Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML.
In: PR Newswire, 2022-10-24
Zeitungsartikel
Zugriff:
Titel: |
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML.
|
---|---|
Zeitschrift: | PR Newswire, 2022-10-24 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|